Novo Nordisk | NVO - Cash And Equivalent

Stock Price
43.35
Daily Change
-3.83 -8.12%
Monthly
-22.89%
Yearly
-50.26%
Q1 Forecast
56.42

Novo Nordisk reported DKK38.94B in Cash and Equivalent for its fiscal quarter ending in March of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 262.61M 44.81M Sep/2025
Aurora Cannabis CAD 95.69M 44.47M Sep/2025
Bausch Health Companies USD 1.31B 419M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Canopy Growth CAD 298.06M 171.86M Sep/2025
Corcept Therapeutics USD 125.14M 22.39M Sep/2025
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 9.79B 6.42B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 147.59M 152.89M Sep/2025
Perrigo USD 432.1M 22.1M Sep/2025
Prestige Brands USD 62.37M 56.73M Dec/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 151.37M 6.66M Sep/2025
Zoetis USD 2.08B 649M Sep/2025